Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
Medpage Today on MSN7d
Survival Win for Pembrolizumab in Early Triple-Negative Breast CancerPD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...
Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...
7don MSN
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
MedPage Today on MSN8d
Another Possible Treatment Option for Intermediate-Stage Liver CancerMedian PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback